Unlike conventional treatments, SynCell's technology offers a tailored, antibiotic-free solution with no risk of resistance.
SynCell Biotechnology, a spinout from Northeastern University, areaddressing this challenge. By developing selenium nanoparticles from MRSA bacteria and incorporating them into wound dressings, MRSA infections can be selectively targeted while preserving beneficial bacteria. Unlike conventional treatments, SynCell's technology offers a tailored, antibiotic-free solution with no risk of resistance. The technology could be used to treat bacterial skin infections or broader antimicrobial applications, and the team are seeking partners for investment and development.